MF trial study question.

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
robtmsstt1
Posts: 23
Joined: Wed Jul 13, 2016 2:18 pm

MF trial study question.

Post by robtmsstt1 » Tue Mar 07, 2017 4:14 pm

Are the patients in the J@J study worse in their condition than the one used in the MAYO study?

biopearl
Posts: 367
Joined: Wed Dec 09, 2015 12:12 am

Re: MF trial study question.

Post by biopearl » Tue Mar 07, 2017 5:42 pm

Yes, they are either patients who responded to Jakafi and then stopped responding or failed to respond in the first place. In other words end stage disease with failure to respond to conventional therapy. They have about a seven month life expectancy. bp

robtmsstt1
Posts: 23
Joined: Wed Jul 13, 2016 2:18 pm

Re: MF trial study question.

Post by robtmsstt1 » Tue Mar 07, 2017 5:49 pm

biopearl wrote:Yes, they are either patients who responded to Jakafi and then stopped responding or failed to respond in the first place. In other words end stage disease with failure to respond to conventional therapy. They have about a seven month life expectancy. bp
Thanks, biopearl i guess i was misled on YMB by william i thought that they were a different subset of patients.

biopearl
Posts: 367
Joined: Wed Dec 09, 2015 12:12 am

Re: MF trial study question.

Post by biopearl » Tue Mar 07, 2017 6:54 pm

I can't speak with certainty as some of the Mayo patients may have overlapped in criterion with the J and J population. Nonetheless the J and J population is distinguished by the end of the line nature of the natural history of their disease and their difficult to treat status.

Post Reply